Aldeyra Therapeutics Files Q2 2024 10-Q

TL;DR

Aldeyra Therapeutics filed its Q2 2024 10-Q. Financials and operations detailed.

AI Summary

Aldeyra Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational details are included in the filing.

Why It Matters

This filing provides investors with a detailed look at Aldeyra Therapeutics' financial health and operational progress during the second quarter of 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Aldeyra Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 2024-06-30 — Reporting Period End Date (The 10-Q covers financial information up to this date.)
• 2023-01-01 — Start Date for Employee Stock Purchase Plan (Indicates the period for which the TwoThousandSixteenEmployeeStockPurchasePlan was active.)
• 2023-06-30 — End Date for Employee Stock Purchase Plan (Indicates the period for which the TwoThousandSixteenEmployeeStockPurchasePlan was active.)
• 2023-04-01 — Start Date for Retained Earnings (Specific quarter for retained earnings reporting.)
• 2023-06-30 — End Date for Retained Earnings (Specific quarter for retained earnings reporting.)

Key Players & Entities

• Aldeyra Therapeutics, Inc. (company) — Filer
• 20240630 (date) — Reporting period end date
• 131 HARTWELL AVENUE (location) — Business address
• LEXINGTON (location) — City in business address
• MA (location) — State in business address
• 02421 (location) — ZIP code in business address
• 781-761-4904 (phone_number) — Business phone number
• Aldexa Therapeutics, Inc. (company) — Former company name
• Neuron Systems Inc (company) — Former company name
• HelioVision Inc (company) — Mentioned in relation to common stock

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq

Filing Documents

• aldx-20240630.htm (10-Q) — 1767KB
• aldx-ex10_1.htm (EX-10.1) — 111KB
• aldx-ex10_2.htm (EX-10.2) — 23KB
• aldx-ex31_1.htm (EX-31.1) — 16KB
• aldx-ex31_2.htm (EX-31.2) — 16KB
• aldx-ex32_1.htm (EX-32.1) — 11KB
• img130887665_0.jpg (GRAPHIC) — 855KB
• 0000950170-24-089238.txt ( ) — 8584KB
• aldx-20240630.xsd (EX-101.SCH) — 960KB
• aldx-20240630_htm.xml (XML) — 960KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION ITEM 1. Condensed Consolidated Financial Statements: 3 Consolidated Balance Sheets at June 30, 2024 (Unaudited) and December 31, 2023 3 Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (Unaudited) 4 Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 (Unaudited) 5 Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2024 and 2023 (Unaudited) 6 Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (Unaudited) 8 Notes to Condensed Consolidated Financial Statements (Unaudited) 9 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 28 ITEM 4.

Controls and Procedures

Controls and Procedures 28

– OTHER INFORMATION

PART II – OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 29 ITEM 1A.

Risk Factors

Risk Factors 29 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 76 ITEM 3. Defaults Upon Senior Securities 76 ITEM 4. Mine Safety Disclosures 76 ITEM 5. Other Information 76 ITEM 6. Exhibits 77

– FINANCI AL INFORMATION

Part I – FINANCI AL INFORMATION

Condensed Consolidated Fi nancial Statements

Item 1. Condensed Consolidated Fi nancial Statements. ALDEYRA THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS June 30, 2024 December 31, (unaudited) 2023 ASSETS Current assets: Cash and cash equivalents $ 31,029,723 $ 142,823,016 Cash equivalent - reverse repurchase agreements 40,000,000 — Marketable securities 49,301,960 — Prepaid expenses and other current assets 5,317,836 4,987,317 Total current assets 125,649,519 147,810,333 Right-of-use assets 391,595 510,814 Fixed assets, net 2,720 5,764 Total assets $ 126,043,834 $ 148,326,911 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 254,434 $ 1,338,057 Accrued expenses 5,842,802 5,536,464 Current portion of debt 15,242,327 15,146,546 Operating lease liabilities 255,039 239,183 Deferred collaboration revenue 6,000,000 — Total current liabilities 27,594,602 22,260,250 Deferred collaboration revenue, long-term — 6,000,000 Operating lease liabilities, long-term 138,893 271,631 Total liabilities 27,733,495 28,531,881 Commitments and contingencies (Notes 3, 9, & 14) Stockholders' equity: Preferred stock, $ 0.001 par value, 15,000,000 shares authorized, none issued and outstanding — — Common stock, voting, $ 0.001 par value; 150,000,000 authorized and 59,414,489 and 59,195,951 shares issued and outstanding, respectively 59,415 59,196 Additional paid-in capital 517,449,424 513,994,982 Accumulated other comprehensive loss ( 9,658 ) — Accumulated deficit ( 419,188,842 ) ( 394,259,148 ) Total stockholders' equity 98,310,339 119,795,030 Total liabilities and stockholders' equity $ 126,043,834 $ 148,326,911 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 ALDEYRA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERA TIONS (Unaudited) Three Months

View Full Filing

View this 10-Q filing on SEC EDGAR